News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Bioject Medical Technologies Inc. (BJCT) And Chronimed/StatScript Announce Supply Agreement



10/19/2005 5:12:38 PM

BEDMINSTER, N.J., Feb. 4 /PRNewswire-FirstCall/ -- Bioject Medical Technologies, Inc. , a leading developer of needle-free drug delivery systems, announced today that it has entered into a supply agreement with Chronimed Inc. , a specialty pharmacy which distributes pharmaceuticals and provides specialized patient management services for people with HIV/AIDS. The agreement calls for the sale of Biojector(R) 2000 (B-2000) needle-free systems and related accessories to Chronimed for distribution to eligible patients who are using FUZEON(R), an AIDS drug developed by Trimeris, Inc. ("Trimeris") in collaboration with Roche. Financial terms of the agreement between Bioject and Chronimed were not disclosed. FUZEON is the first and only fusion inhibitor for the treatment of HIV. Unlike other HIV drugs that work after HIV has entered the human immune cell, FUZEON works outside the CD4 cell, blocking HIV from entering the cell.

Early data recently presented at the HIV DART -- Frontiers in Drug Development for Antiretroviral Therapies medical conference found that patients who were administered a single dose of FUZEON with Bioject's B-2000 achieved equivalent drug levels in the blood compared to those who were administered FUZEON with the standard needle and syringe. In a separate study, the British Columbia Centre for Excellence in HIV/AIDS presented early experience with the use of the B-2000 needle-free injection device in a cohort of twelve FUZEON patients. Data from this small cohort of patients experiencing tolerability problems with needle-based FUZEON therapy, who switched to needle-free administration for up to 4 weeks, was encouraging and supported the rationale to further assess the feasibility of needle-free administration of FUZEON.

Commenting on the agreement, Jim O'Shea, Bioject's Chairman, President and Chief Executive Officer stated, "We are very pleased to enter into this supply agreement with Chronimed. The B-2000 has been used to deliver millions of injections in a wide range of healthcare settings since approval in 1994. We believe our needle-free technology presents a beneficial alternative to conventional needle-syringe administration for HIV patients who may consider or have already incorporated FUZEON as part of their treatment regimens. We hope that this development will represent the beginning of the successful application of our company's needle-free drug delivery products to the needs of HIV infected patients and their healthcare providers."

Tony Zappa, Chronimed's Executive Vice President of Operations commented, "We are excited about the opportunity to offer Bioject's B-2000 needle-free system as part of an overall evaluation and support program for individuals that are using FUZEON in their HIV/AIDS treatment regimen and those who have delayed starting FUZEON due to concerns about using a needle and syringe. Given our involvement with FUZEON patients and their healthcare providers from its initial launch in March 2003, we have gained unique and extensive experience with injection-related issues encountered during therapy. We have designed our evaluation and support program in order to successfully assess these issues in an effort to further improve patient outcomes and clinician experiences with FUZEON."

Effective February 4th, 2005, Chronimed will begin to offer FUZEON patients access to their comprehensive evaluation and support program that includes the B-2000 as a new injection option. For more information on the evaluation and support program or to refer a patient, contact Chronimed at 866-694-6670.

Bioject Medical Technologies Inc., based in Bedminster, New Jersey, and Portland, Oregon, is an innovative developer and manufacturer of needle-free drug delivery systems. Needle-free injection works by forcing medication at high speed through a tiny orifice held against the skin. This creates a fine stream of high-pressure fluid penetrating the skin and depositing medication in the tissue beneath. The Company is focused on developing mutually beneficial agreements with leading pharmaceutical, biotechnology, and veterinary companies.

Chronimed Inc. is a specialty pharmacy that distributes prescription drugs and provides specialized therapy management services for people with certain conditions, including HIV/AIDS, organ transplants, and diseases treated with biotech injectable medications. Chronimed works with patients, physicians and other health care providers, pharmaceutical manufacturers, health plans and insurers, and government agencies to improve clinical and economic outcomes. Chronimed's website address is http://www.chronimed.com/.

For more information on Bioject, visit http://www.bioject.com/.

Bioject Medical Technologies, Inc.

CONTACT: John Gandolfo, Chief Financial Officer of Bioject MedicalTechnologies Inc., +1-908-470-2800, ext. 5102, or jgandolfo@bioject.com; orBrad Schumacher, Director of Investor Relations of Chronimed Inc.,+1-952-979-3942; or John Baldissera of BPC Financial Marketing, +800-368-1217,or bschumacher@chronimed.com, for Bioject Medical Technologies Inc.


Read at BioSpace.com


comments powered by Disqus
   
HIV/AIDS

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES